



ORISON PHARMA INTERNATIONAL,
Vill, Khari, kala Amb (H.P)




Page 1 of 1

QUALITY CONTROL DEPARTMENT
CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Name of Product	FRASIX – 40	A.R. No.	OPI-FGT4043/23
Generic Name	Furosemide Tablets IP 40 mg	Received date	23/11/2023
Batch No.	23H – T1778	Analysis Completion /Release Date	24/11/2023
Mfg. Date	11/2023	Batch Size	5.0 Lac Tablets
Best Before /Expiry	10/2025	Mfg. Lic. No.	MNB/07/644 & MB/07/645

Sr. No.	Test	Specifications	Results
1.	Description	Off white colour round shape biconvex both side plain uncoated tablet.	Off white colour round shape biconvex both side plain uncoated tablet.
2.	Identification		
2.1	By UV	When examined in the range 220 nm to 360 nm the final solution obtained in the assay shows three absorption maxima at about 228 nm 271 nm and 333 nm.	Complies
2.2	By Chemically	A green colour is produced which changes to deep red.	Complies
3.	Average wt. of tablet	190 mg $\pm$ 7.5% (175.8 mg to 204.3 mg)	189.1 mg
4.	Uniformity of wt.	Average weight. $\pm$ 7.5%	Max +4.29% Min -3.25%
5.	Disintegration Time	NMT 15 Minutes	04 min 16 sec
6.	Friability	NMT 1.0%	0.30%
7.	Dissolution Test	NLT 75% of the stated amount	Min – 77.24% Max +81.61%
8.	Related Substances	Should be comply as per IP	Complies
9.	Hardness	NLT 3.0 kg/cm ²	3.4 kg/cm ²
10.	ASSAY : (Each uncoated tablet contains)		
10.1	Furosemide IP 40 mg	36.0 mg to 44.0 mg & 90% to 110%	39.39 mg & 98.48%

Remark: In the opinion of the undersigned the sample referred to above is standard quality as complies as per IP/BP/USP/HH Specification.

Signatories	Prepared By (QC)	Checked By (QC)	Approved By (QC)
Name	Bhavana	Rizwan	
Designation	Chemist	Sr. Executive	
Signature & Date:	 24/11/2023	 24/11/2023	

OPI/QC/057/F05-00